SORBIDIOL 150® / SORBIDIOL 300® / SORBIDIOL 450® Tablets
Composition:
SORBIDIOL 150® Tablets
Each uncoated tablet contains:
- Ursodeoxycholic Acid I.P. ........................................ 150 mg
- Excipients ...................................................................…….. q.s.
SORBIDIOL 300® Tablets
Each uncoated tablet contains:
- Ursodeoxycholic Acid I.P. ........................................ 300 mg
- Excipients ...................................................................…….. q.s.
SORBIDIOL 450® Tablets
Each uncoated tablet contains:
- Ursodeoxycholic Acid I.P. ........................................ 450 mg
- Excipients ...................................................................…….. q.s.
Description
- Ursodeoxycholic acid (UDCA), a naturally occurring hydrophilic bile acid, derived from cholesterol, is present as a minor fraction of the total human bile acid pool. Oral administration of SORBIDIOL® Tablets increases this fraction in a dose-related manner, to become the major biliary acid, replacing/displacing toxic concentrations of endogenous hydrophobic bile acids that tend to accumulate in cholestatic liver disease. In addition to the replacement and displacement of toxic bile acids, other mechanisms of action include cytoprotection of the injured bile duct epithelial cells (cholangiocytes) against toxic effects of bile acids, inhibition of apoptosis of hepatocytes, immunomodulatory effects, and stimulation of bile secretion by hepatocytes and cholangiocytes.
Indications
- Chronic intrahepatic cholestatic diseases, including primary biliary Cirrhosis and Primary Sclerosing Cholangitis.
- Cholelithiasis: UDCA is effective in dissolving small gallstones (<5 mm).